Becton Dickinson shares hit record high after US FDA clears return of drug infusion system https://ift.tt/u1l3xjh

Becton Dickinson said it expects to begin shipping the devices and recognizing revenue in its fiscal year 2024. It said it does not expect any material incremental revenue contribution from the Alaris infusion system for the rest of fiscal year 2023, which ends Sept. 30.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3YhpK0F